An interventional study of Atorvastatin 80mg and Placebo in Postoperative Atrial Fibrillation, sponsored by Odense University Hospital. Recruiting at 1 site in Denmark. Open to participants aged 60 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Atrial Fibrillation by Odense University Hospital — 2 open to participants now, 2 under way, none of them phase 3. Atrial Fibrillation · Odense University Hospital.
Among the 10 studies in Atrial Fibrillation by Odense University Hospital, this one is one of 2 that started in 2022, is one of 4 with no phase, and was the 7th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 10 studies in Atrial Fibrillation by Odense University Hospital are open now, in 1 country. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 60 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 266 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 141 across the 6 interventional studies, 182 across the 4 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Atrial Fibrillation by Odense University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Statins have rapid and significant actions that have potentially important (but not yet proven) implications for postoperative atrial fibrillation and cardiac protection in patients undergoing cardiac surgery.
The focus of this study is, therefore, on patients having surgical aortic valve replacement (with aortotomy) and the development of postoperative atrial fibrillation (POAF). Our aims are: to examine the ability of a clinically durable Atorvastatin prophylactic regime to prevent the development of POAF and other postoperative complications in these patients.
Patients will be randomized to Atorvastatin 80mg or placebo 7 to 14 days preoperative until 30 days postoperative - a total of 37 to 44 days of treatment.
The medication will be double blinded.
The randomized studie will address the following hypotheses in patients undergoing open heart operation with solitary aortic valve replacement with a bioprosthetic valve that
1) 7 to 14 days preoperative and until 30 days postoperative treatment with Atorvastatin 80 mg daily reduces the incidence of POAF in statin-naïve patients.
Trial Participants:
Enrolment for the study is planned to start February 2022 and continue until 266 patients have been enrolled.
DEFINITION OF POAF:
Postoperative AF (I48) is defined as irregular RR-intervals without a traceable p-wave before each QRS complex during at least 30 seconds or entire 12-lead ECG in symptomatic or asymptomatic patients with no prior history of atrial fibrillation or flutter are considered4. Continuous ECG monitoring (8-lead ward monitor) will recognise AF during the entire hospitalization. Anamnesis, electronic health record (EHR), or confirmatory rhythm strip or 12-lead ECG of AF until 30th postoperative day are also considered.
We will also report the burden of atrial fibrillation, and treatment with a rate controlling drug, antiarrhythmic drug, or electrical cardioversion.
Course of action:
Patients undergoing elective surgical aortic valve replacement with bioprosthesis at the Department of Cardiac Surgery at Odense University Hospital will be offered participation in the study.
Potentially eligible patients will be screened according to inclusion/exclusion criteria at the time after eligibility of surgery. This is assessed at a multidisciplinary team (MDT) conference (with attendance of cardiologist, cardiac surgeons and anaesthesiologist) based on clinical evaluation, echocardiographic ultrasound, coronary angiography and lung function test.
Patients eligible to participate in the study will be presented with the information of the study at the time of their out-patient appointment, according to normal routine at Odense University Hospital. At this appointment the patient receives a physical examination and journal record is obtained by a cardiac surgeon (approximately 7 to 14 days prior to planned surgery).
The study-information will be given by one of the participating doctors, while the patient has been informed of the possibility of bringing an assessor of their choice. The information will be delivered in a quiet room blocked to other appointments in the Department of Cardiothoracic Surgery.
During this meeting the patient will be informed of the purpose of this study and the written patient information will be submitted in detail. Patients will be given as much time as wanted after the oral information has been delivered to decide if they wish to participate in the study. Patients will be offered the possibility to call one of the doctors taking part in this study during this time, in case of additional questions. Subjects can leave the study at any time for any reason if they wish to do so, without any consequences.
Signed informed consent will be provided prior to any research procedures. A subject is registered when signed informed consent has been provided and assigned a subject identification code by the computer-generated code. A subject is randomized when a treatment and a randomisation number has been provided. A subject is considered enrolled in the study once the subject is randomized.
Patient data from EHR will be conducted according to study endpoints after signed informed consent is provided. Signed consent gives sponsor and sponsors representatives
Randomization:
Allocation to a numbered treatment pack (Atorvastatin or placebo - blinded) Randomization scheme will be set-up by OPEN data manager with control for beta-blockers and age, and then randomization per se will be executed with the use of REDCap.
The following will be recorded at the day of randomization:
Collect baseline blood sample:
Commence study medication/treatment
Perioperative interventions and outcomes from the day of surgery to the day of discharge:
Blood samples:
Assessment at/after discharge from hospital:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Drug: Atorvastatin 80mg
Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Drug: Placebo
Dosage: 80 mg Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Form: Tablets Frequency: 1 tabl. per day. Duration: From 7 to 14 days prior to surgery until 30 days postoperative
Number of Participants with POAF - In-hospital
In-hospital incidence of POAF assessed by continuous ECG monitoring (8-lead ward monitor).
Time frame: In-hospital up to 10 days
Number of Participants with POAF - Early
Early assessed by anamnesis, electronic health record (EHR), or confirmatory rhythm strip or 12-lead ECG of AF
Time frame: Early (≤30 days) incidence of POAF
Total duration of POAF - In-hospital
Total duration of POAF episodes experienced in-hospital (unit: hours)
Time frame: In-hospital up to 10 days
Rate of All-cause mortality - In-hospital
To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes. Number of deaths in each group.
Time frame: In hospital up to 10 days
Rate of All-cause mortality - Early
To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes. Number of deaths in each group.
Time frame: Early (≤30 days)
Rate of All-cause mortality - intermediate
To evaluate the effect of prophylactic regime administration of Atorvastatin on clinical outcomes. Number of deaths in each group.
Time frame: intermediate (1 year)
Myocardial injury - Tn
Injury assessed by serial Troponin measurements. Unit:ng/l
Time frame: After surgery until discharge up to 10 days.
Myocardial injury - CKMB
Injury assessed by serial CKMB measurements. Unit: μg/l.
Time frame: After surgery until discharge up to 10 days.
Stroke - Early
Number of patients with stroke in each group.
Time frame: Early (≤30 days)
Stroke - Intermediate
Number of patients with stroke in each group.
Time frame: Intermediate (1 year)
Trans ischemic attack - Early
Number of patients with trans ischemic attack in each group.
Time frame: Early (≤30 days)
Trans ischemic attack - Intermediate
Number of patients with trans ischemic attack in each group.
Time frame: Intermediate (1 year)
Myocardial infarction - Early
Number of patients with Myocardial infarction in each group.
Time frame: Early (≤30 days)
Myocardial infarction - Intermediate
Number of patients with Myocardial infarction in each group.
Time frame: Intermediate (1 year)
Permanent pacemaker - Early
Number of patients with Permanent pacemaker in each group.
Time frame: Early (≤30 days)
Permanent pacemaker - Intermediate
Number of patients with Permanent pacemaker in each group.
Time frame: Intermediate (1 year)
ICD implantation - Early
Number of patients with ICD implantation in each group.
Time frame: Early (≤30 days)
ICD implantation - Intermediate
Number of patients with ICD implantation in each group.
Time frame: Intermediate (1 year)
Acute kidney injury - Early
Number of patients with Acute kidney injury in each group.
Time frame: Early (≤30 days)
Acute kidney injury - Intermediate
Number of patients with Acute kidney injury in each group.
Time frame: Intermediate (1 year)
LVEF
Describe echocardiography assessed differences in pre and postoperative measurements of LVEF(left ventricular ejection fraction) between groups. Unit: %
Time frame: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Strain
Describe echocardiography assessed differences in pre and postoperative measurements of Strain between groups.Unit: %
Time frame: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Peak gradient
Describe echocardiography assessed differences in pre and postoperative measurements of peak gradient between groups. Unit: mmHg
Time frame: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Mean gradient
Describe echocardiography assessed differences in pre and postoperative measurements of mean gradient between groups. Unit: mmHg
Time frame: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
TAPSE
Describe echocardiography assessed differences in pre and postoperative measurements of TAPSE (tricuspid annular plane systolic excursion) between groups. Unit: mm
Time frame: Before surgery compared with prior to discharge (On the 3rd to 5th postoperative day).
Length of stay on ICU
Length of stay on ICU after surgery. Unit: Days
Time frame: Day of surgery to the day of discharge from ICU. Up to 52 weeks.
Length of stay in hospital
Length of stay in hospital after surgery. Unit: Days
Time frame: Day of surgery to the day of discharge. Up to 52 weeks.
Plan to share: Yes — Data will be available in anonymized form in accordance with GDPR upon reasonable request. Rules for external researchers to apply for and access data will be laid out towards the end of the study.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: TBA
Access criteria: TBA
Started Feb 2022 (actual). Primary completion is estimated for Dec 2027, 70 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 70 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atorvastatin